Racial and socioeconomic disparities among patients with chronic lymphocytic leukemia: Analysis of Surveillance, Epidemiology, and End Results program data.

Authors

null

Adam Kittai

Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Adam Kittai , Ying Huang , James L. Fisher , Seema Bhat , Michael R. Grever , Electra D. Paskett , Kerry Anne Rogers , Jennifer Ann Woyach

Organizations

Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Division of Hematology, The Ohio State University, Columbus, OH

Research Funding

No funding received

Background: Therapy for chronic lymphocytic leukemia (CLL) has changed dramatically over the past 20 years. With the cost of new therapies and rapid practice changes, it is unclear if patients (pts) are benefiting equally from this progress. We assessed Surveillance, Epidemiology, and End Results (SEER) program data to determine how race and socioeconomic status (SES) affect survival for pts with CLL. Methods: CLL cases reported to 18 SEER Program registries from 2006 – 2018 were included. Pt characteristics such as age at diagnosis (dx), sex, year (yr) of dx, race, and SES as determined by rural/urban census tract residence (RUCA), and neighborhood (as represented by the Yost Index, a composite measure of 7 variables assessing different aspects of the SES of a census tract) were collected and analyzed. Multivariable cox regression (MVA) was used to determine adjusted odds of survival. Two separate databases were utilized, one which included data to 2018, and another which contained SES data but only had data available to 2016. Results: 46,605 cases from 2009 – 2018 were identified without SES data. The median age was 70 yrs, 60% were male, and there was an even distribution of patients diagnosed with CLL annually from 2009 – 2018. Of the cases with race reported, 89.9% were white, 7.3% Black, 2.4% Asian/Pacific islander, and 0.3% American Indian/Alaska Native. After a median follow up of 47 months, the median 3, 5, and 10 yr overall survival (OS) was 79.5%, 69.5%, and 48.8%, respectively. MVA showed Black race (HR 1.5, 95% CI 1.4 – 1.6) as the strongest independent prognostic variable for worse OS controlling for yr of dx, suggesting race was a significant factor in OS in the era of modern therapies. Using the linked RUCA and Yost tertiles for SES, 47,867 cases of CLL from 2006 – 2016 were analyzed. Median age, sex, and race distribution were similar to the prior analysis. MVA showed American Indian/Alaska Native, and Black race as independent prognostic variables for worse OS, and Yost group 2 and 3, representing higher SES, were found to be significant independent prognostic variables for improved OS (Table 1). In this analysis, race remained an independent variable for worse OS after controlling for SES. Conclusions: Black race and low SES are prognostic of OS in CLL. Further research is needed to determine whether this is due to access to therapy, quality of care, social determinants of heath, or disease biology.

MVA for OS by demographic variables.

Variable
HR (95% CI)
Wald P-value
Age*
1.09 (1.08 - 1.09)
<.0001
Male vs. Female
1.33 (1.28 - 1.37)
<.0001
Yr of Dx*
0.99 (0.98 - 1.00)
0.0045
Race vs. White

American Indian/Alaska Native

Asian/Pacific Islander

Black


1.41 (1.03 - 1.92)

0.97 (0.86 - 1.09)

1.33 (1.24 - 1.41)


0.03

0.57

<.0001
Yost vs. Group 1

Group 2

Group 3


0.82 (0.79 - 0.86)

0.68 (0.65 - 0.71)


<.0001

<.0001
RUCA Rural vs. Urban
0.97 (0.91 - 1.02)
0.24

*1 year increase.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7542)

DOI

10.1200/JCO.2022.40.16_suppl.7542

Abstract #

7542

Poster Bd #

195

Abstract Disclosures

Similar Abstracts

First Author: Adam Kittai

Abstract

2023 ASCO Annual Meeting

Impact of disadvantaged socioeconomic and demographic status on survival in Kaposi sarcoma.

First Author: Michelle Swedek

First Author: Justin Michael Barnes

First Author: Shivani Shah